drugset
drugset / Trial / NCT02599532

Pharmacokinetics of Apixaban in Nephrotic Syndrome

NCT02599532 ↗

Phase 1 Completed 21 enrolled University of North Carolina, Chapel Hill North Carolina Translational and Clinical Sciences Institute · collab
Non-randomizedParallel-groupOpen-labelOther

Summary

This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.

Timeline

Start
2017-04-30
Primary completion
2019-06-28
Completion
2019-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 10 mg —

Indications

nephrotic syndrome proteinuria